Related Experiment Video

Updated: Jun 1, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Genetic determinants of on-clopidogrel high platelet reactivity

Gianluca Campo1, Matteo Miccoli, Matteo Tebaldi

  • 1Cardiovascular Institute, Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy. cmpglc@unife.it

Platelets
|June 2, 2011
PubMed

Insights

Genetic variations affect how patients respond to clopidogrel, impacting treatment effectiveness and risks. Understanding these gene polymorphisms is key to optimizing antiplatelet therapy and preventing cardiovascular events.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Clopidogrel is widely used to prevent vascular complications in atherothrombotic patients and after percutaneous coronary intervention.
  • A subset of patients exhibits high platelet reactivity despite clopidogrel therapy, limiting its efficacy.
  • Clopidogrel metabolism is influenced by various enzymes, including cytochrome P450 family members and P-glycoprotein-1, which are subject to genetic polymorphisms.

Purpose of the Study:

  • To review the principal gene polymorphisms that influence on-clopidogrel platelet reactivity (PR).
  • To explore the relationship between these genetic variations and long-term clinical outcomes in patients receiving dual antiplatelet therapy.

Main Methods:

  • Literature review of studies investigating clopidogrel metabolism and pharmacogenetics.
  • Analysis of gene polymorphisms affecting enzymes involved in clopidogrel absorption, conversion, and activation.
  • Correlation of identified polymorphisms with on-clopidogrel PR and clinical events (ischemic and bleeding).

Main Results:

  • Several gene polymorphisms reduce active metabolite concentration and increase on-clopidogrel PR.
  • The CYP2C19*17 polymorphism is associated with increased clopidogrel metabolism and enhanced platelet inhibition.
  • Studies link specific gene polymorphisms to increased risks of both ischemic and bleeding complications.

Conclusions:

  • Gene polymorphisms significantly impact clopidogrel efficacy and safety.
  • Understanding these genetic factors is crucial for personalized antiplatelet therapy strategies.
  • Further research is warranted to fully elucidate the clinical implications of clopidogrel-related gene polymorphisms.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...